{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T21:55:00Z","timestamp":1788990900683,"version":"build-2803163510"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T00:00:00Z","timestamp":1661299200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>The Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial demonstrated that rivaroxaban 2.5\u00a0mg BID with aspirin 100\u00a0mg was more effective than aspirin 100\u00a0mg daily alone for the prevention of cardiovascular (CV) death, stroke, or myocardial infarction in patients with stable coronary artery disease (CAD) or peripheral artery disease (PAD). We aimed to examine the cost-effectiveness of rivaroxaban using patient-level data from the COMPASS trial.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>We performed an in-trial analysis and extrapolated our results for 33 years using a two-state Markov model with a 1-year cycle length. Hospitalization events, procedures, and study drugs were documented for patients. We applied country-specific (Canada, France, and Germany) direct healthcare system costs (in USD) to healthcare resources consumed by patients. Average cost per patient during the trial (mean follow-up of 23 months), quality-adjusted life years (QALYs), and lifetime cost-effectiveness were calculated. Costs of events and procedures were reduced with rivaroxaban 2.5\u00a0mg BID with aspirin. The addition of rivaroxaban 2.5\u00a0mg BID increased total costs for the combination group. Over a lifetime horizon (in trial +33 years), rivaroxaban plus aspirin was associated with 1.17 QALYs gained, yielding an incremental cost-effectiveness ratio (ICER) of $3946\/QALY, $9962\/QALY, and $10\u00a0264\/QALY in Canada, France, and Germany, respectively. PAD and polyvascular disease subgroups had lower ICERs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Rivaroxaban 2.5\u00a0mg twice daily plus aspirin compared with aspirin alone reduces direct healthcare costs. After acquisition costs of rivaroxaban, the lifetime cost-effectiveness of 2.5\u00a0mg twice daily plus aspirin is highly cost-effective in Canada, France, and Germany.<\/jats:p>\n                  <jats:p>(COMPASS ClinicalTrials.gov identifier: NCT01776424)<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ehjqcco\/qcac054","type":"journal-article","created":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T22:28:08Z","timestamp":1661380088000},"page":"502-510","source":"Crossref","is-referenced-by-count":12,"title":["The cost-effectiveness of rivaroxaban with or without aspirin in the COMPASS trial"],"prefix":"10.1093","volume":"9","author":[{"given":"Andre","family":"Lamy","sequence":"first","affiliation":[{"name":"Population Health Research Institute, McMaster University , Hamilton, Ontario , Canada"},{"name":"CADENCE Research Group, Hamilton Health Sciences , Hamilton, Ontario , Canada"},{"name":"Department of Surgery, McMaster University , Hamilton, Ontario , Canada"},{"name":"Department of Health Research Methods, Evidence, and Impact, McMaster University , Hamilton, Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Eikelboom","sequence":"additional","affiliation":[{"name":"Population Health Research Institute, McMaster University , Hamilton, Ontario , Canada"},{"name":"Department of Medicine, McMaster University , Hamilton, Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wesley","family":"Tong","sequence":"additional","affiliation":[{"name":"Population Health Research Institute, McMaster University , Hamilton, Ontario , Canada"},{"name":"CADENCE Research Group, Hamilton Health Sciences , Hamilton, Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Yuan","sequence":"additional","affiliation":[{"name":"Population Health Research Institute, McMaster University , Hamilton, Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shrikant I","family":"Bangdiwala","sequence":"additional","affiliation":[{"name":"Population Health Research Institute, McMaster University , Hamilton, Ontario , Canada"},{"name":"Department of Health Research Methods, Evidence, and Impact, McMaster University , Hamilton, Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jackie","family":"Bosch","sequence":"additional","affiliation":[{"name":"Population Health Research Institute, McMaster University , Hamilton, Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Connolly","sequence":"additional","affiliation":[{"name":"Population Health Research Institute, McMaster University , Hamilton, Ontario , Canada"},{"name":"Department of Medicine, McMaster University , Hamilton, Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Lonn","sequence":"additional","affiliation":[{"name":"Population Health Research Institute, McMaster University , Hamilton, Ontario , Canada"},{"name":"Department of Health Research Methods, Evidence, and Impact, McMaster University , Hamilton, Ontario , Canada"},{"name":"Department of Medicine, McMaster University , Hamilton, Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles R","family":"Dagenais","sequence":"additional","affiliation":[{"name":"Institut Universitaire de Cardiologie et de Pneumologie de Qu\u00e9bec , Qu\u00e9bec, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelley R H","family":"Branch","sequence":"additional","affiliation":[{"name":"University of Washington Medical Center , Seattle, WA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Jhih","family":"Wang","sequence":"additional","affiliation":[{"name":"Comparative Health Outcomes, Policy and Economics Institute, School of Pharmacy, University of Washington , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak L","family":"Bhatt","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital Heart and Vascular Center, Harvard Medical School , Boston, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Probstfield","sequence":"additional","affiliation":[{"name":"Division of Cardiology, University of Washinton , Seattle, WA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Ertl","sequence":"additional","affiliation":[{"name":"Department of Medicine I, University of W\u00fcrzburg , W\u00fcrzburg Germany"},{"name":"Comprehensive Heart Failure Center, University Hospital , W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"St\u00f6rk","sequence":"additional","affiliation":[{"name":"Department of Medicine I, University of W\u00fcrzburg , W\u00fcrzburg Germany"},{"name":"Comprehensive Heart Failure Center, University Hospital , W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P Gabriel","family":"Steg","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Universit\u00e9 Paris Diderot , Paris , France"},{"name":"H\u00f4pital Bichat, Assistance Publique-H\u00f4pitaux de Paris , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Aboyans","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Dupuytren University Hospital, and Inserm 1094 & IRD, NET, Limoges University , Limoges , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Durand-Zaleski","sequence":"additional","affiliation":[{"name":"Assistance Publique H\u00f4pitaux de Paris, URC Eco and Sant\u00e9 Publique, H\u00f4pital Henri Mondor , Cr\u00e9teil , France"},{"name":"Health Economics Research Unit, Universit\u00e9 Paris Est Cr\u00e9teil , Cr\u00e9teil , France"},{"name":"INSERM ECEVE UMR 1123 , Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Ryden","sequence":"additional","affiliation":[{"name":"Cardiology Unit, Department of Medicine K2, Karolinska Institutet , Stockholm , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salim","family":"Yusuf","sequence":"additional","affiliation":[{"name":"Population Health Research Institute, McMaster University , Hamilton, Ontario , Canada"},{"name":"Department of Health Research Methods, Evidence, and Impact, McMaster University , Hamilton, Ontario , Canada"},{"name":"Department of Medicine, McMaster University , Hamilton, Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,8,24]]},"reference":[{"key":"2023080708272953600_bib1","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N Engl J Med"},{"key":"2023080708272953600_bib2","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.cjca.2017.06.001","article-title":"Rationale, design and baseline characteristics of participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial","volume":"33","author":"Bosch","year":"2017","journal-title":"Can J Cardiol"},{"key":"2023080708272953600_bib3","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1016\/j.jacc.2014.03.016","article-title":"ACC\/AHA statement on cost\/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology\/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines","volume":"63","author":"Anderson","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2023080708272953600_bib4","article-title":"Developing NICE guidelines: the manual | Guidance and guidelines | NICE","author":"NICE"},{"key":"2023080708272953600_bib5","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.cjca.2011.08.112","article-title":"The cost of clopidogrel use in atrial fibrillation in the ACTIVE-A trial","volume":"28","author":"Lamy","year":"2012","journal-title":"Can J Cardiol"},{"key":"2023080708272953600_bib6","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.jdiacomp.2014.02.012","article-title":"Cost implications of the use of basal insulin glargine in people with early dysglycemia: the ORIGIN trial","volume":"28","author":"Lamy","year":"2014","journal-title":"J Diabetes Complicat"},{"key":"2023080708272953600_bib7","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1016\/j.athoracsur.2014.06.046","article-title":"The cost implications of off-pump versus on-pump coronary artery bypass graft surgery at one year","volume":"98","author":"Lamy","year":"2014","journal-title":"Ann Thorac Surg"},{"key":"2023080708272953600_bib8","article-title":"Herzlich willkommen \u2026, InEK GmbH","author":"Anon"},{"key":"2023080708272953600_bib9","author":"Anon","journal-title":"Stats ATIH"},{"key":"2023080708272953600_bib10","doi-asserted-by":"crossref","first-page":"792","DOI":"10.3111\/13696998.2011.627405","article-title":"The cost implications of the use of telmisartan or ramipril in patients at high risk for vascular events: the ONTARGET study","volume":"14","author":"Lamy","year":"2011","journal-title":"J Med Econ"},{"key":"2023080708272953600_bib11","first-page":"1","article-title":"Projecting effectiveness after ending a randomized controlled trial: a two-state Markov","author":"Yuan","year":"2020","journal-title":"Int J Technol Assess Health Care"},{"key":"2023080708272953600_bib12","first-page":"1","article-title":"United States life tables","volume":"66","author":"Arias","year":"2017","journal-title":"Natl Vital Stat Rep Cent Dis Control Prev Natl Cent Health Stat Natl Vital Stat Syst"},{"key":"2023080708272953600_bib13","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1177\/0272989X9301300409","article-title":"Markov models in medical decision making: a practical guide","volume":"13","author":"Sonnenberg","year":"1993","journal-title":"Med Decis Making"},{"key":"2023080708272953600_bib14","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1002\/sim.4274","article-title":"The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt","volume":"30","author":"Royston","year":"2011","journal-title":"Stat Med"},{"key":"2023080708272953600_bib15","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/1471-2288-13-152","article-title":"Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome","volume":"13","author":"Royston","year":"2013","journal-title":"BMC Med Res Methodol"},{"key":"2023080708272953600_bib16","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/00005650-200503000-00003","article-title":"US valuation of the EQ-5D health states: development and testing of the D1 valuation model","volume":"43","author":"Shaw","year":"2005","journal-title":"Med Care"},{"key":"2023080708272953600_bib17","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"},{"key":"2023080708272953600_bib18","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/hec.1730","article-title":"Budget allocation and the revealed social rate of time preference for health","volume":"21","author":"Paulden","year":"2012","journal-title":"Health Econ"},{"key":"2023080708272953600_bib19","doi-asserted-by":"crossref","first-page":"485","DOI":"10.2217\/cer.15.38","article-title":"Systematic overview of cost-effectiveness thresholds in ten countries across four continents","volume":"4","author":"Schwarzer","year":"2015","journal-title":"J Comp Eff Res"},{"key":"2023080708272953600_bib20","volume-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"Drummond","edition":"3rd ed."},{"key":"2023080708272953600_bib21","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.amjmed.2012.01.014","article-title":"An international model to predict recurrent cardiovascular disease","volume":"125","author":"Wilson","year":"2012","journal-title":"Am J Med"},{"key":"2023080708272953600_bib22","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ijcard.2018.06.091","article-title":"Cost-effectiveness of rivaroxaban and aspirin compared to aspirin alone in patients with stable cardiovascular disease: an Australian perspective","volume":"270","author":"Ademi","year":"2018","journal-title":"Int J Cardiol"},{"key":"2023080708272953600_bib23","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1177\/2047487318817910","article-title":"Cost-effectiveness of low-dose rivaroxaban and aspirin versus aspirin alone in people with peripheral or carotid artery disease: an Australian healthcare perspective","volume":"26","author":"Zomer","year":"2019","journal-title":"Eur J Prev Cardiol"},{"key":"2023080708272953600_bib24","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1093\/cvr\/cvz278","article-title":"Health economic evaluation of rivaroxaban in the treatment of patients with chronic coronary artery disease or peripheral artery disease","volume":"116","author":"Cowie","year":"2020","journal-title":"Cardiovasc Res"},{"key":"2023080708272953600_bib25","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1080\/13696998.2021.1997024","article-title":"Clinical implications and cost-effectiveness analysis of rivaroxaban in patients with coronary artery disease or peripheral arterial disease in the Netherlands","volume":"24","author":"Spoorendonk","year":"2021","journal-title":"J Med Econ"},{"key":"2023080708272953600_bib26","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1001\/jamacardio.2016.1747","article-title":"Cost-effectiveness analysis of sacubitril\/valsartan vs enalapril in patients with heart failure and reduced ejection fraction","volume":"1","author":"Gaziano","year":"2016","journal-title":"JAMA Cardiol"},{"key":"2023080708272953600_bib27","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1016\/j.jacc.2020.03.029","article-title":"Cost-effectiveness of alirocumab in patients with acute coronary syndromes: the ODYSSEY OUTCOMES trial","volume":"75","author":"Bhatt","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2023080708272953600_bib28","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jacc.2021.04.083","article-title":"Mortality benefit of rivaroxaban plus aspirin in patients with chronic coronary or peripheral artery disease","volume":"78","author":"Eikelboom","year":"2021","journal-title":"J Am Coll Cardiol"}],"container-title":["European Heart Journal - Quality of Care and Clinical Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjqcco\/advance-article-pdf\/doi\/10.1093\/ehjqcco\/qcac054\/45877218\/qcac054.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjqcco\/article-pdf\/9\/5\/502\/51045930\/qcac054.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjqcco\/article-pdf\/9\/5\/502\/51045930\/qcac054.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T08:27:47Z","timestamp":1691396867000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjqcco\/article\/9\/5\/502\/6674756"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,24]]},"references-count":28,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,8,24]]},"published-print":{"date-parts":[[2023,8,7]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjqcco\/qcac054","relation":{},"ISSN":["2058-5225","2058-1742"],"issn-type":[{"value":"2058-5225","type":"print"},{"value":"2058-1742","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,8]]},"published":{"date-parts":[[2022,8,24]]}}}